references
STRATEGY
of which close to EUR 400 million has already been secured to date. We will stay focused on the key elements that have been essential to our success: our partnerships with private sector actors, key for us to access the necessary expertise and data to bring a treatment through to the hands of patients; the support
of public actors, which has been the lifeline of our endeavours; and the participation of research communities and civil society in endemic countries to ensure patients’ needs remain at the forefront of our efforts. For this particular reason, this business plan will be translated into a regional strategic plan, with the expansion and development of
DNDi’s regional offices, particularly those in neglected disease-endemic regions. These close associations, for some now more than a decade long, will remain a fundamental part of the set-up of DNDi and assure the process of mutual learning for change for the benefit of the most neglected populations in the most neglected health and social systems.
6 treatments delivered EUR 400 million raised
2015
16 -18 treatments
2023
treatments delivered EUR 250 million needed for a total of EUR 650 million investment
10 -12 additionnal
2023
INFLUENCE THE R&D LANDSCAPE FOR NEGLECTED DISEASES
DEVELOP TREATMENTS FOR PEOPLE SUFFERING FROM NEGLECTED DISEASES
STRENGTHEN RESEARCH CAPACITY
In the new Business Plan, the founding principles upon which DNDi is built are also reinforced:
• a patients’ needs-driven approach; • a steadfast commitment to promote open sharing of research knowledge and data while ensuring an access-oriented approach to intellectual property; • the fostering of innovative, collaborative partnerships with public and private sectors; • the diversification of funding sources to ensure independence.
8 › DNDi Annual Report 2015
